Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Cheng AL, et al. Among authors: burock k. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16. Lancet Oncol. 2009. PMID: 19095497 Clinical Trial.
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K, Escudier B. Beck J, et al. Among authors: burock k. Ann Oncol. 2011 Aug;22(8):1812-23. doi: 10.1093/annonc/mdq651. Epub 2011 Feb 15. Ann Oncol. 2011. PMID: 21324953 Free article. Clinical Trial.
Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann HW, Meier CR, Lohrmann HP, Ruffert U, Hänel M, Bodenstein H, Neubauer A, Ehninger G, Wolf HH, Kolbe K, Burock K, Zander AR, Nitz U. Kröger N, et al. Among authors: burock k. J Clin Oncol. 2006 Aug 20;24(24):3919-26. doi: 10.1200/JCO.2005.04.0352. J Clin Oncol. 2006. PMID: 16921043 Clinical Trial.
Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study.
Locatelli F, Antmen B, Kang HJ, Koh K, Takahashi Y, Kupesiz A, Dias Matos MGA, Chopra Y, Bhat S, Im HJ, Güngör T, Lu MY, Stefanelli T, Rosko C, St Pierre A, Burock K, Smith Y, Sinclair K, Diaz-de-Heredia C. Locatelli F, et al. Among authors: burock k. Lancet Haematol. 2024 Aug;11(8):e580-e592. doi: 10.1016/S2352-3026(24)00174-1. Epub 2024 Jul 10. Lancet Haematol. 2024. PMID: 39002551 Clinical Trial.
Bleeding patterns with the levonorgestrel-releasing intrauterine system when used for heavy menstrual bleeding in women without structural pelvic pathology: a pooled analysis of randomized controlled studies.
Jensen J, Mansour D, Lukkari-Lax E, Inki P, Burock K, Fraser IS. Jensen J, et al. Among authors: burock k. Contraception. 2013 Jan;87(1):107-12. doi: 10.1016/j.contraception.2012.08.022. Epub 2012 Oct 4. Contraception. 2013. PMID: 23040140 Clinical Trial.